-The Hindu Ranbaxy's fraudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its fraudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...
More »SEARCH RESULT
Total Matching Records found : 4031
Dinesh Thakur, an ex-Ranbaxy employee who blew the whistle on the company, interviewed by The Economic Times
-The Economic Times Indian pharmaceutical company Ranbaxy recently paid $500 million to the US government to settle civil and criminal charges for making fraudulent statements to the US FDA and selling adulterated drugs in the US. Dinesh Thakur, an ex-Ranbaxy employee who blew the whistle on the company, talks to ET about the five-year long investigation and the future of generic drug Companies in the US. Edited Excerpts: * You think you...
More »Ponzi scam: Over 150 petitions found on rail track
-PTI Burdwan (WB): About 150 sheets, allegedly copies of petitions filed by depositors related to the Saradha chit fund scam, were found on the side of rail tracks between Kalna and Guptipara stations of Eastern Railway's Howrah-Burdwan section on Sunday. GRP sources said about 150 papers, claimed to be petitions of depositors from Murshidabad and Jharkhand, were spotted ying on the sides of the rail track at Purbo Satgachia station by local...
More »New bank licences: The contenders -Dinesh Unnikrishnan
-Live Mint A SWOT analysis of 24 Companies that are drawing up plans for their entry into banking Mumbai: The deadline for applying for a banking licence expires on 1 July. At least two dozen Companies, both in the private and public sectors, are busy drawing up plans for their entry into banking, being opened up again a decade after the Reserve Bank of India (RBI) allowed the entry of two...
More »USFDA scrutiny: Will pharma majors like Ranbaxy, Wockhardt be affected in long-term? -G Seetharaman
-The Economic Times Japanese Companies do not mind erring on the side of caution. They are known to think longer and harder than their counterparts in other countries about big decisions, especially when it comes to entering a new market or acquiring a foreign company. But Japan's third biggest drugmaker Daiichi Sankyo would now wish it had spent more time doing due diligence on Ranbaxy Labs, in which it bought a...
More »
